 Early-initiated zidovudine therapy disease low levels persistent retrovirus mice hybrid mouse strain genotype Friend virus complex FV zidovudine ZDV times days min initial viral exposure strain mice develops FV-specific neutralizing antibodies viremia splenic virus titers splenomegaly eventual FV-associated death exposed mice ZDV splenomegaly detectable viremia last drug treatment day single animal demonstrable virus spleen focal immunoenzyme detectable virus weeks splenic virus weeks None animals holding period placebo-treated mice low levels virus latent virus splenocytes cell line propagate FV cells times replication virus amplification significant increase number mice positive virus ZDV treatment virus exposure effective FV-induced splenomegaly death low levels persistent retrovirus mice